| Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination M Scully, D Singh, R Lown, A Poles, T Solomon, M Levi, D Goldblatt, ... New England Journal of Medicine 384 (23), 2202-2211, 2021 | 1034 | 2021 |
| Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. M Scully, BJ Hunt, S Benjamin, R Liesner, P Rose, F Peyvandi, B Cheung, ... British journal of haematology 158 (3), 2012 | 1019 | 2012 |
| Updated international consensus report on the investigation and management of primary immune thrombocytopenia D Provan, DM Arnold, JB Bussel, BH Chong, N Cooper, T Gernsheimer, ... Blood advances 3 (22), 3780-3817, 2019 | 832 | 2019 |
| Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura M Scully, SR Cataland, F Peyvandi, P Coppo, P Knöbl, ... New England Journal of Medicine 380 (4), 335-346, 2019 | 758 | 2019 |
| Caplacizumab for acquired thrombotic thrombocytopenic purpura F Peyvandi, M Scully, JA Kremer Hovinga, S Cataland, P Knöbl, H Wu, ... New England Journal of Medicine 374 (6), 511-522, 2016 | 600 | 2016 |
| Clinical features of vaccine-induced immune thrombocytopenia and thrombosis S Pavord, M Scully, BJ Hunt, W Lester, C Bagot, B Craven, A Rampotas, ... New England Journal of Medicine 385 (18), 1680-1689, 2021 | 524 | 2021 |
| A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura M Scully, V McDonald, J Cavenagh, BJ Hunt, I Longair, H Cohen, ... Blood, The Journal of the American Society of Hematology 118 (7), 1746-1753, 2011 | 488 | 2011 |
| Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies M Scully, S Cataland, P Coppo, J De La Rubia, KD Friedman, JK Hovinga, ... Journal of thrombosis and haemostasis 15 (2), 312-322, 2017 | 418 | 2017 |
| Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease KJ Carss, G Arno, M Erwood, J Stephens, A Sanchis-Juan, S Hull, K Megy, ... The American Journal of Human Genetics 100 (1), 75-90, 2017 | 409 | 2017 |
| Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features M Scully, H Yarranton, R Liesner, J Cavenagh, B Hunt, S Benjamin, ... British journal of haematology 142 (5), 819-826, 2008 | 408 | 2008 |
| Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13 M Scully, H Cohen, J Cavenagh, S Benjamin, R Starke, S Killick, I Mackie, ... British journal of haematology 136 (3), 451-461, 2007 | 339 | 2007 |
| How I treat disseminated intravascular coagulation M Levi, M Scully Blood, The Journal of the American Society of Hematology 131 (8), 845-854, 2018 | 284 | 2018 |
| Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes M Scully, M Thomas, M Underwood, H Watson, K Langley, RS Camilleri, ... Blood, The Journal of the American Society of Hematology 124 (2), 211-219, 2014 | 274 | 2014 |
| Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura M Scully, P Knöbl, K Kentouche, L Rice, J Windyga, R Schneppenheim, ... Blood, The Journal of the American Society of Hematology 130 (19), 2055-2063, 2017 | 241 | 2017 |
| How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome M Scully, T Goodship British journal of haematology 164 (6), 759-766, 2014 | 203 | 2014 |
| Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse JP Westwood, H Webster, S McGuckin, V McDonald, SJ Machin, M Scully Journal of Thrombosis and Haemostasis 11 (3), 481-490, 2013 | 191 | 2013 |
| Management of thrombotic thrombocytopenic purpura: current perspectives P Blombery, M Scully Journal of blood medicine, 15-23, 2014 | 187 | 2014 |
| Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study RJ Perry, A Tamborska, B Singh, B Craven, R Marigold, P Arthur-Farraj, ... The Lancet 398 (10306), 1147-1156, 2021 | 178 | 2021 |
| The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, ... Kidney international 97 (6), 1287-1296, 2020 | 142 | 2020 |
| Evaluation of laboratory assays for anti‐platelet factor 4 antibodies after ChAdOx1 nCOV‐19 vaccination S Platton, A Bartlett, P MacCallum, M Makris, V McDonald, D Singh, ... Journal of Thrombosis and Haemostasis 19 (8), 2007-2013, 2021 | 140 | 2021 |
